Cell Biology

G Protein-Coupled Receptors (GPCRs)

Q: What does the seven-transmembrane (7-TM) topology actually do?

Seven alpha-helices crisscross the lipid bilayer, forming a barrel with the ligand-binding cavity nestled inside. When the agonist binds, helices — especially TM5 and TM6 — pivot, opening a cleft on the cytoplasmic side that the G protein can dock into. The 7-TM scaffold is ancient and conserved: bacterial bacteriorhodopsin uses the same fold to pump protons. Crystallography of β2-adrenergic with bound G protein (Kobilka, 2011 Nobel) confirmed the TM6 outward swing as the activation hallmark.

Q: What's the difference between Gαs, Gαi, Gαq, and Gα12/13?

Each Gα subfamily routes the signal to a different downstream enzyme. Gαs stimulates adenylyl cyclase → raises cAMP. Gαi inhibits adenylyl cyclase → lowers cAMP, and also opens GIRK potassium channels. Gαq activates phospholipase C-β → produces IP3 and DAG, releasing Ca²⁺. Gα12/13 activates RhoGEFs → drives cytoskeletal rearrangement. The same receptor can sometimes couple to multiple Gα families, which is exploited by 'biased agonists' — drugs that preferentially activate one branch.

Q: Do GPCRs only signal through G proteins?

No. β-arrestin, originally identified as a desensitization scaffold, also nucleates its own signaling cascades — MAP kinase activation, ubiquitin ligase recruitment, transcriptional effects. Some drugs are 'biased agonists' that engage arrestin signaling without activating G proteins (TRV027 for heart failure, for example). The line between 'G-protein-coupled' and 'arrestin-coupled' is now blurred enough that some prefer the older name 'seven-transmembrane receptors'.

The seven-helix antenna behind one in three modern drugs

GPCRs are a superfamily of seven-transmembrane receptors that translate extracellular ligands — light, hormones, neurotransmitters, odorants — into intracellular signals through heterotrimeric G proteins. The human genome encodes about 800 GPCRs, half of them dedicated to olfaction. Roughly 30% of FDA-approved drugs target this single receptor family, including beta-blockers, antihistamines, opioids, and antipsychotics.

Human genome count~800 receptors (~400 sensory)
Topology7 transmembrane α-helices
Signal partnerGαβγ heterotrimer + β-arrestin
Drug-target share~30% of FDA approvals
NobelLefkowitz & Kobilka, 2012
Activation timescaleMilliseconds to seconds

Interactive visualization

Press play, or step through manually. The visualization is yours to drive — try it before reading on.

Open visualization fullscreen ↗

Watch the 60-second explainer

A condensed visual walkthrough — narrated, captioned, under a minute.

How a GPCR fires

Picture the cell membrane as a phospholipid sea, and a GPCR as a cylinder of seven α-helices threaded through it like a barrel of staves. The extracellular loops form a binding pocket facing outward; the cytoplasmic loops form a docking face for the G protein on the inside. The whole receptor sits inert until its ligand arrives.

The activation sequence is mechanical, not chemical magic:

Ligand binds. Adrenaline, photons (in rhodopsin, the ligand is the receptor's covalently bound retinal, isomerized by light), an odorant, a peptide hormone — all squeeze into the helical bundle.
Helices repack. Transmembrane helix 6 (TM6) swings outward by roughly 14 Å on the cytoplasmic side; TM5 follows. This is the universal hallmark of GPCR activation, captured in dozens of crystal and cryo-EM structures.
The intracellular cleft opens. A pocket appears on the cytoplasmic face that exactly fits the C-terminal α5 helix of Gα.
The receptor catalyzes nucleotide exchange. Inserting α5 destabilizes Gα's grip on GDP. GTP, abundant in the cytoplasm, replaces it.
The G protein splits. Gα-GTP separates from Gβγ. Both halves diffuse along the inner membrane leaflet to find their effectors.
Effectors fire. Adenylyl cyclase produces cAMP, phospholipase C cuts PIP2 into IP3 + DAG, ion channels open or close, and so on — depending on which Gα subtype was engaged.
The clock runs out. Gα's slow intrinsic GTPase (sped up by RGS proteins) hydrolyzes GTP to GDP. Gα reunites with Gβγ. Signal terminates. Receptor, meanwhile, gets phosphorylated by GRKs, recruits β-arrestin, and is dragged into a clathrin pit for recycling or destruction.

The whole loop runs in milliseconds for fast neurotransmitter receptors and seconds for slower hormonal ones. A single ligand-bound receptor can activate many G proteins before it's quenched — built-in amplification.

Why GPCRs dominate pharmacology

Surface accessibility. Drugs do not need to cross the membrane to reach the binding site.
Druggable pockets. The ligand cavity is deep and small-molecule-shaped, unlike the flat interfaces typical of intracellular signaling proteins.
Tissue selectivity. Receptor subtypes (β1 vs β2, μ vs δ vs κ opioid, H1 vs H2 histamine) cluster in different tissues, allowing precise targeting.
Functional selectivity. Biased agonists can pull G-protein vs β-arrestin pathways apart — for example, separating analgesia from constipation in opioid design.
Sensory ubiquity. Every photon you see, every scent you smell, every flavor you taste, and most of your hormone responses pass through a GPCR.
Genetic tractability. Mutations cause well-defined diseases (retinitis pigmentosa from rhodopsin mutations, nephrogenic diabetes insipidus from V2 receptor loss, familial male precocious puberty from constitutively active LHCGR).

The five GPCR classes

Class	Letter	Examples	Distinguishing feature
Rhodopsin-like	A	Adrenergic, opioid, dopamine, rhodopsin, olfactory	~85% of all GPCRs; short N-terminus; conserved DRY and NPxxY motifs
Secretin-like	B1	Glucagon receptor, GLP-1, PTH, calcitonin	Long extracellular N-terminus binds peptide hormones; targets of semaglutide
Adhesion	B2	ADGRG1 (GPR56), latrophilins, CELSRs	Huge N-termini with adhesion domains; auto-cleavage at GAIN domain exposes a tethered agonist
Glutamate	C	mGluR1–8, GABA-B, calcium-sensing receptor, taste-sweet/umami	Venus flytrap extracellular domain; obligate dimers
Frizzled / Taste-2	F	Frizzled (Wnt), Smoothened, Taste-2 (bitter)	Cysteine-rich extracellular domain; Smoothened is a hedgehog effector
Other / Orphan	—	~140 unmatched receptors	No known endogenous ligand; deorphanization is an active research field

The original Kolakowski A–F scheme is now usually merged with the GRAFS classification (Glutamate, Rhodopsin, Adhesion, Frizzled, Secretin). Class A alone accounts for the vast majority of clinical drug targets.

Downstream branches: the four Gα families

Family	Effector	Second messenger	Example receptors	Toxin probe
Gαs	Adenylyl cyclase ↑	cAMP up → PKA	β-adrenergic, glucagon, V2-vasopressin, D1 dopamine	Cholera toxin (locks on)
Gαi/o	Adenylyl cyclase ↓; GIRK channels open	cAMP down; K⁺ efflux	μ-opioid, M2 muscarinic, α2-adrenergic, D2 dopamine	Pertussis toxin (locks off)
Gαq/11	Phospholipase C-β	IP3 + DAG → Ca²⁺ & PKC	α1-adrenergic, M1/M3 muscarinic, AT1, H1 histamine	YM-254890 (selective inhibitor)
Gα12/13	RhoGEFs (p115-RhoGEF, LARG)	RhoA → cytoskeleton	Thrombin (PAR1), LPA, S1P	None (genetic only)
Gβγ (released)	PLC-β2/3, GIRK, Ca²⁺ channels, PI3K-γ	Multiple, parallel	All trimer-coupled receptors	—
β-Arrestin (G-independent)	MAPK scaffolds, ubiquitin ligases	ERK, JNK pulses	AT1, μ-opioid (biased agonism)	—

The Gαq → IP3 → Ca²⁺ branch and the Gαs → cAMP → PKA branch are the two most heavily studied. The Ca²⁺ pulse can drive contraction (smooth muscle), secretion (β-cell insulin), or transcription (NFAT). cAMP/PKA in turn phosphorylates CREB to switch on cAMP-responsive genes.

Real-world consequences

Cholera. Cholera toxin's A1 subunit ADP-ribosylates Gαs on Arg201, abolishing its GTPase. Gαs is locked GTP-on, cAMP soars, intestinal CFTR dumps chloride and water — the lethal diarrhea is a single-residue trick.
Whooping cough. Pertussis toxin ADP-ribosylates Gαi on a C-terminal cysteine, preventing its activation by the receptor. Gαi-mediated brakes on cAMP fail; cells over-respond.
Heart failure and beta-blockers. Chronic β1-adrenergic stimulation drives heart remodeling. Blocking it with metoprolol or bisoprolol slows progression and saves lives — the modern foundation of heart-failure pharmacotherapy.
Asthma. Salbutamol (β2-adrenergic agonist) relaxes bronchial smooth muscle by raising cAMP, opening the airways within minutes.
Vision. Rhodopsin is a GPCR whose ligand is covalently attached 11-cis-retinal. A photon isomerizes it to all-trans; the receptor activates transducin (Gαt), which gates cGMP-specific phosphodiesterase. The cell hyperpolarizes — this is the first chemical step of seeing.
GLP-1 agonists. Semaglutide (Ozempic, Wegovy), tirzepatide — class B GPCR agonists that have rewritten obesity and type-2 diabetes treatment in the 2020s.

Variants and special cases

Constitutive activity. Some mutant GPCRs activate G proteins without any ligand. Activating LHCGR mutations cause familial male precocious puberty; activating thyroid-stimulating hormone receptor mutations cause hyperthyroid nodules.
Inverse agonists vs antagonists. An antagonist blocks an agonist; an inverse agonist additionally suppresses constitutive activity below baseline. Most "antihistamines" sold today are inverse agonists at H1.
Allosteric modulators. Cinacalcet binds the calcium-sensing receptor at a site distinct from Ca²⁺ itself, sensitizing the receptor — a positive allosteric modulator (PAM) used in hyperparathyroidism.
Biased agonists. TRV130 (oliceridine) preferentially activates G-protein over β-arrestin signaling at the μ-opioid receptor, aiming for analgesia with less respiratory depression — though its real-world advantage remains debated.
Heterodimers. Many class C GPCRs (GABA-B, taste sweet/umami T1R1/T1R3) are obligate dimers. Class A receptors can form transient heterodimers (μ-δ opioid) with distinct pharmacology.
Adhesion GPCRs. Class B2 receptors auto-cleave their N-terminus at the GAIN domain. The C-terminal stub harbors a "tethered agonist" peptide that flips into the seven-helix bundle when the N-terminus is mechanically pulled — a force sensor in the receptor family.

Common pitfalls and misconceptions

"GPCRs only signal through G proteins." β-arrestin runs its own signaling network, and biased ligands can engage one branch and not the other.
"Desensitization is a bug." It is a feature — without it, the system would saturate. But it is also why opioid tolerance, β-agonist tachyphylaxis, and chronic-allergy-medication drift happen.
"All GPCRs use cAMP." Only Gαs- and Gαi-coupled ones touch cAMP directly. Gαq goes through IP3/Ca²⁺/DAG; Gα12/13 goes through Rho.
"One receptor, one G protein." Most GPCRs couple promiscuously to multiple Gα subtypes, often with different efficiencies for different agonists.
"Rhodopsin is unique because of light." Rhodopsin uses the same TM6-outward swing, the same heterotrimeric G protein logic — only the agonist (covalent retinal isomerization) is unusual.
"Endocytosis means the signal is over." Internalized GPCRs continue to signal from endosomes, and some pathways (parathyroid hormone receptor, TSH receptor) require endosomal signaling for full effect.

Frequently asked questions

Why are GPCRs such popular drug targets?

Three reasons converge. First, they sit on the cell surface, so drugs need not cross the membrane. Second, their ligand-binding pockets are deep, well-defined, and usually small-molecule-friendly — unlike the flat protein-protein interfaces of intracellular signaling. Third, the family is enormous (~800 in humans) and tissue-specific, so a drug for one receptor (β1-adrenergic in the heart) often spares another (β2 in the lung). About 30% of FDA-approved drugs hit GPCRs, generating tens of billions in annual sales.

What does the seven-transmembrane (7-TM) topology actually do?

Seven α-helices crisscross the lipid bilayer, forming a barrel with the ligand-binding cavity nestled inside. When the agonist binds, helices — especially TM5 and TM6 — pivot, opening a cleft on the cytoplasmic side that the G protein can dock into. The 7-TM scaffold is ancient and conserved: bacterial bacteriorhodopsin uses the same fold. Crystallography of β2-adrenergic with bound G protein (Kobilka, 2011 Nobel) confirmed the TM6 outward swing as the activation hallmark.

How does the Gαβγ heterotrimer cycle work?

At rest, Gα binds GDP and is locked to Gβγ. When the activated GPCR contacts the trimer, it acts as a guanine-nucleotide exchange factor — it pries GDP off Gα. GTP rushes in (cytoplasmic GTP is roughly tenfold more abundant). GTP-bound Gα separates from Gβγ; both halves now signal independently. Gα has intrinsic GTPase activity, accelerated by RGS proteins. Once Gα hydrolyzes GTP back to GDP, it reassociates with Gβγ and the cycle resets.

What's the difference between Gαs, Gαi, Gαq, and Gα12/13?

Each Gα subfamily routes to a different downstream enzyme. Gαs stimulates adenylyl cyclase → raises cAMP. Gαi inhibits adenylyl cyclase → lowers cAMP, and opens GIRK potassium channels. Gαq activates phospholipase C-β → IP3 and DAG, releasing Ca²⁺. Gα12/13 activates RhoGEFs → drives cytoskeletal rearrangement. The same receptor can couple to multiple Gα families, which is exploited by biased agonists.

How does cholera toxin hijack GPCR signaling?

Cholera toxin's A1 subunit ADP-ribosylates Gαs on Arg201, blocking its GTPase activity. Gαs is locked in the GTP-bound state, continuously stimulating adenylyl cyclase and raising cAMP without limit. In gut epithelium, soaring cAMP activates CFTR chloride channels; chloride efflux drags water, producing the watery diarrhea characteristic of cholera. Pertussis toxin does the mirror image — ADP-ribosylates Gαi, preventing its activation.

What is GPCR desensitization?

After activation, GPCR kinases (GRKs) phosphorylate the receptor's cytoplasmic tail. This recruits β-arrestin, which physically blocks further G-protein coupling and links the receptor to clathrin-coated pits for endocytosis. Internalized receptors either recycle (resensitization) or are sent to lysosomes (downregulation). This is why opioids develop tolerance: chronic morphine drives μ-opioid receptor downregulation.

Do GPCRs only signal through G proteins?

No. β-arrestin, originally a desensitization scaffold, also nucleates its own signaling cascades — MAP kinase activation, ubiquitin ligase recruitment, transcriptional effects. Some drugs are biased agonists that engage arrestin signaling without activating G proteins. The line between G-protein-coupled and arrestin-coupled is blurred enough that some prefer the older name "seven-transmembrane receptors."